[#item_full_content]
BIEL, Switzerland–(BUSINESS WIRE)– #ClinicalTrials–STIMIT AG announced today it is enrolling patients in its FDA Investigational Device Exemption (IDE) clinical trial, “STIMIT ACTIVATOR 1 PIVOTAL STUDY,” with world renowned clinical centers. STIMIT’s initial therapy in its platform uses noninvasive diaphragm neurostimulation and is designed to preserve diaphragm thickness in patients who are on invasive mechanical ventilation (MV) and thus are at risk of diaphragmatic dysfunction/atrophy. The IDE study will e